Exelixis, Inc.

Signal Pharmaceuticals, Inc.

Chris Allen Buhr

Sunghoon Ma

Tae-Gon Baik

Longcheng Wang

John M Nuss

Shripad S Bhagwat

John J Sapienza

Qi Chao

Yoshitaka Satoh

Ronald J Albers

Steven T Sakata

Kiran Sahasrabudhe

Veronique Plantevin

Rachel Ferri

Neel Kumar Anand

Tsze Tsang

Csaba J Peto

Kenneth D Rice

Larisa Dubenko

Katherine Lara

Bryan K S Yeung

Joerg Bussenius

Abigail R Kennedy

Charles M Blazey

Angie Inyoung Kim

Jean-Claire Limun Manalo

Owen Joseph Bowles

Steven Charles Defina

Zerom Tesfai

Yong Wang

Timothy Patrick Forsyth

James William Leahy

David J Matthews

Naing N Aay

Larry Wayne Mann

Morrison B Mac

Jeff Z Chen

Grace Mann

Simona Costanzo

Tai Phat Huynh

Peter Lamb

Erick Wang Co

Craig Stacy Takeuchi

Cristiana A Zaharia

Jeffry Kimo Curtis

Amy Lew Tsuhako

Lisa Esther Dalrymple

Sergey Epshteyn

Mohamed Ibrahim

Xian Shi

Anagha Abhijit Joshi

Arlyn Arcalas

Kevin Luke Schnepp

Jason R Harris

Eileen E Jackson-Ugueto

Baili Chen

Stephanie Ng

Jeffrey Kimo Curtis

Nicole Miller

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.

Pyrazole kinase modulators and methods of use

The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture

The invention is directed to Compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds. 

Pyridopyrimidinone inhibitors of PI3K&#x3b1; for the treatment of cancer

The invention is directed to Compounds of Formula I: optionally as a single stereoisomer or mixture of stereoisomers thereof, and additionally optionally as a pharmaceutically acceptable salt thereof; as well as methods of making and using the compounds.

Pyridopyrimidinone inhibitors of PI3K&#x3b1; and mTOR

Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha

A compound according to Formula I or II: wherein R, R, R, L, and Land Lare as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

Tropane compounds

This invention relates to compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compositions containing such compounds. Even more specifically, the invention relates to compounds that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Methods of therapeutically or prophylactically using the compounds and compositions to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amounts of such compounds.

Protein kinase modulators and methods of use

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R, Rand A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Methods of using indazole derivatives as JNK inhibitors

This invention is generally directed to Indazole Derivatives having the following structure: or pharmaceutically acceptable salt thereof, wherein R, Rand A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure:wherein R, Rand A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Indazole derivatives as JNK inhibitors and compositions and methods related thereto

Growing community of inventors

Redwood City, CA, United States of America

Chris Allen Buhr